ClinicalTrials.gg
Not yet recruitingNCT07944404ProPhISUpdated Nov 18, 2026

Prophylactic Phasix™ Mesh for Incisional Hernia Prevention in IBD Surgery: A Prospective Multicenter Study

An interventional study of Phasix Mesh in Inflammatory Bowel Disease (IBD), Chrohn's Disease and Ulcerative Colitis (UC), sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionColitis, UlcerativeRegistry: Inflammatory Bowel DiseasesReclassifiedWhy we changed it
Registry
Inflammatory Bowel Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Colitis, Ulcerative
Why
  1. The study's listed conditions name Colitis, Ulcerative, a narrower term within Inflammatory Bowel Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Not applicable, Interventional, and Prevention

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to evaluate the incidence of incisional hernia, detected by ultrasound imaging, two years after surgery in patients with Inflammatory Bowel Disease (IBD) undergoing either open or minimally invasive abdominal surgery with the use of prophylactic Phasix™ Mesh reinforcement. The study focuses on consecutive adult patients aged 18 years or older with a confirmed histological diagnosis of Crohn's disease or Ulcerative Colitis who are scheduled for elective abdominal surgery, specifically minimally invasive surgery requiring a periumbilical incision for specimen extraction or open abdominal surgery via a midline incision for patients undergoing their second or subsequent abdominal operation for IBD. The main questions it aims to answer are: what is the rate of 24-month incisional hernia as diagnosed by ultrasound imaging in the prospective study population, and how do secondary outcomes such as postoperative pain, quality of life, surgical site occurrences, and 90-day complication rates compare across these surgical strata? If there is a comparison group: Researchers will compare participants who received open surgery to those who received minimally invasive surgery to see if there are significant differences in the 24-month incisional hernia rates, complication profiles, and recovery metrics. Participants will undergo their planned abdominal surgery according to standard institutional care pathways, during which the study device-the Phasix™ Mesh-will be positioned to reinforce either the periumbilical extraction site in minimally invasive procedures or the midline incision in open surgeries using a standardized onlay technique. Following surgery, participants will be asked to complete a series of main tasks and evaluations, which include providing daily self-reported pain ratings on a Visual Analog Scale during hospitalization, attending scheduled follow-up visits at 30 days, 6 months, 12 months, and 24 months post-surgery, undergoing clinical evaluations and wound inspections with standardized photographic documentation at each visit, completing validated questionnaires including the Short-Form Health Survey-36, Ventral Hernia Pain Questionnaire, and Carolinas Comfort Scale at specified postoperative time points, and undergoing delegated ultrasound imaging of the entire length of the incision in both supine resting and dynamic states during the 12-month and 24-month follow-up visits to detect any occult or overt fascial defects or herniation.

02

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Chrohn's Disease
  • Ulcerative Colitis (UC)

Browse trials for

03

In context

Colitis, Ulcerative Reclassified

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

This study's planned enrollment of 150 is above the median of 70 across 1,238 interventional studies indexed under Colitis, Ulcerative.

Browse Colitis, Ulcerative studies →

Lead sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna is the lead sponsor of 517 studies on the registry; 292 are open to participants now.

Compared within Colitis, Ulcerative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Inflammatory Bowel Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients aged ≥ 18 years at the time of screening.
  • Confirmed ( proven) diagnosis of Crohn's disease or Ulcerative Colitis.
  • Scheduled to undergo abdominal surgery, specifically:

    • Minimally invasive surgery (laparoscopic or robotic) requiring a periumbilicaln incision for specimen extraction.
    • Open abdominal surgery (laparotomy) via a midline incision, for patients undergoing their second or subsequent abdominal operation for IBD.
  • Willingness and ability to provide .
  • Willingness and ability to comply with follow-up requirements, including ultrasound examinations.

Exclusion criteria

Exclusion Criteria:

  • Emergency surgery (e.g., for perforation with gross contamination, hemodynamic instability requiring immediate life-saving surgery without time for prophylactic mesh consideration).
  • Presence of an existing incisional hernia at the planned incision site.
  • Known allergy or to any components of Phasix™ Mesh. In particular, known allergy to tetracycline hydrochloride or kanamycin sulfate.
  • Current gross abdominal sepsis or infection that, in the surgeon's judgment, would contraindicate mesh placement.
  • less than two years.
  • Pregnant or breastfeeding women.
  • Participation in another interventional trial that might confound the study results.
  • Previous mesh placement at the index incision site (for open surgery patients)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    MIS with Phasix Mesh Reinforcement

    Patients with Inflammatory Bowel Disease undergoing elective minimally invasive (laparoscopic or robotic) abdominal surgery who receive prophylactic Phasix Mesh reinforcement of the periumbilical specimen extraction site using a standardized technique.

    Device: Phasix Mesh

Interventions

  • DevicePhasix Mesh

    A fully resorbable monofilament scaffold (Phasix Mesh) placed during elective abdominal surgery to reinforce either the periumbilical specimen extraction site in minimally invasive surgery or the midline incision in open surgery, using a standardized onlay technique.

06

What researchers measure

Primary outcomes

  1. the rate of 24-month incisional hernia

    diagnosed by ultrasound imaging

    Time frame: baseline

Secondary outcomes

  1. rate of 12-month incisional hernia

    Time frame: baseline

  2. median value of the participants-reported pain

    Time frame: study visits after surgey

  3. The median value of the Ventral Hernia Pain Questionnaire (VHPQ)

    Time frame: after surgery

  4. The median value of the Short-Form Health Survey-36 (SF-36)

    Time frame: after surgery

  5. The median value of the Carolinas Comfort Scale (CCS)

    Time frame: after surgery

  6. The median difference in the 24-month VAS scores

    Time frame: 24 month after surgery

  7. The rate of 90-day postoperative complications classified according to the Clavien-Dindo scale

    Time frame: 90 after surgery

  8. The rate of 90-day reoperations

    Time frame: 90 after surgery

  9. The rate of 24-month incisional hernia between the participants who received open surgery and those who received MIS.

    Time frame: 24 months after surgery

  10. The median difference in the 24-month VHPQ scores

    Time frame: 24 months after surgery

  11. The median difference in the 24-month SF-36 scores

    Time frame: 24 months after surgery

  12. The median difference in the 24-month CCS scores

    Time frame: 24 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 226 non-industry interventional studies with no phase under Colitis, Ulcerative, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 56. This study's planned 24 months is below that.

Counting every sponsor, half of 237 studies reached it within 34 months; a quarter within 15 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 18, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 31, 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07944404
Responsible party
Matteo Rottoli (MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna) — Principal investigator
First posted
Nov 18, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 18, 2026

Study contacts

Matteo Rottoli, MD
Contact
matteo.rottoli@unibo.it
+39 0512144807

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion